Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30249643.
- Also identified by DOI 10.1073/pnas.1802724115 and PMC identifier 6187182.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Retinal degenerative diseases are generally characterized by a permanent loss of light-sensitive retinal neurons known as photoreceptors, or their support cells, the retinal pigmented epithelium (RPE). Metabolic dysfunction has been implicated as a common mechanism of degeneration. In this study, we used the drug metformin in a gain-of-function approach to activate adenosine monophosphate-activated protein kinase (AMPK). We found that treatment protected photoreceptors and the RPE from acute injury and delayed inherited retinal degeneration. Protection was associated with decreased oxidative stress, decreased DNA damage, and increased mitochondrial energy production. To determine whether protection was a local or a systemic effect of metformin, we used AMPK retinal knockout mice and found that local expression of AMPK catalytic subunit α2 was required for metformin-induced protection. Our data demonstrate that increasing the activity of AMPK in retinal neurons or glia can delay or prevent degeneration of photoreceptors and the RPE from multiple types of cell-death triggers.
Medical subject headings
- AMP-Activated Protein Kinases
- Disease Models, Animal
- Metformin
- Photoreceptor Cells
- Retinal Degeneration
- Retinal Pigment Epithelium